Background. Elevated fibroblast growth factor-23 (FGF23) levels increase the risk of cardiovascular diseases in patients with chronic kidney disease (CKD). We aimed to compare the effects of different dietary interventions, lower versus higher phosphate levels, on FGF23 in patients with CKD. Methods. We conducted electronic literature searches of Medline, PubMed, Embase and the Cochrane Library for publications up to 29 October 2016 for randomized clinical trials that compared lower versus higher phosphate dietary interventions in adults with CKD. The primary outcome was the difference in change-from-baseline FGF23 levels between intervention groups. Considering the difference in measurement units between intact FGF23 and C-terminal FGF23 assays, the treatment effect was analysed as the standardized mean difference (SMD) with the 95% confidence interval (CI). Results. We identified five trials enrolling a total of 94 normophosphataemic patients with Stage 3B CKD. The study duration ranged from 1 to 12 weeks. Compared with higher phosphate diets, lower phosphate diets tended to reduce FGF23 levels (SMD À0.74, 95% CI À1.54 to 0.07, P ¼ 0.07). Subgroup analyses showed a trend (P for interaction ¼ 0.09) towards a better FGF23-lowering effect by lower phosphate diets in studies using the intact FGF23 assay (SMD À1.14, 95% CI À2.24 to À0.04) than those using the C-terminal FGF23 assay (SMD À0.05, 95% CI À0.67 to 0.57).
I N T R O D U C T I O N
Chronic kidney disease (CKD) is a global health burden, with a high prevalence ranging from 8% to 16% worldwide [1] [2] [3] , and places a substantial economic cost on health care systems [4] [5] [6] . The risk of cardiovascular morbidity and mortality in patients with CKD is far greater than those in the general population [7] [8] [9] . Among the risk factors for cardiovascular disease in patients with CKD, elevated fibroblast growth factor-23 (FGF23) levels plays a major role with independent pathophysiological mechanisms [10] [11] [12] . Epidemiological studies suggest that elevation of FGF23 is strongly associated with left ventricular hypertrophy [13, 14] , and elevated FGF23 is an independent risk factor for congestive heart failure and mortality [15] [16] [17] .
FGF23 is a phosphaturic hormone that increases the rate of urinary phosphate excretion and inhibits renal production of 1, 25-dihydroxyvitamin D [18, 19] , thus helping mitigate hyperphosphataemia in patients with CKD [20] . Elevated FGF23 is a common manifestation of CKD that develops earlier than hyperphosphataemia or secondary hyperparathyroidism [21, 22] . Evidence that FGF23 levels increase with dietary phosphate loading and decrease with restriction has stimulated interest in developing dietary interventions to reduce FGF23 levels in CKD patients [12, 23, 24] . However, randomized clinical trials (RCTs) assessing the effects of a lower phosphate diet on FGF23 levels in patients with CKD has yielded conflicting results [25] [26] [27] [28] . The aim of this systematic review and metaanalysis was to synthesize results from RCTs comparing the effect of treatment with a lower versus a higher phosphate diet on FGF23 levels in patients with CKD.
M A T E R I A L S A N D M E T H O D S

Data sources and literature searches
Electronic literature searches of Medline, PubMed, Embase and the Cochrane Library were conducted for publications up to 29 October 2016. The search terms included CKD, fibroblast growth factor and dietary phosphorus. The detailed study protocol and search strategies are provided in Appendix 1 of the Supplementary data.
Study selection
We included RCTs with parallel or cross-over design, which compared diets of different phosphate levels, lower versus higher, in CKD patients >18 years of age. The included studies had to report FGF23 levels at baseline and the end of the trial for each intervention group, or differences in the change in FGF23 levels between intervention groups, as the effect measure. Studies evaluating patients with any stage of CKD or patients under dialysis were included.
Data extraction and quality assessment
Two investigators (W.-C.T. and H.-Y.W.) independently extracted relevant information from the included studies and evaluated the methodological quality of the eligible trials using the Cochrane Collaboration's tool for assessing risk of bias (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other sources of bias) [29, 30] . For cross-over trials, other sources of bias included the appropriateness of the cross-over design, randomized order of receiving treatments, carry-over effects, unbiased data and corrected analysis for paired data [29, 30] . We contacted the authors for clarification regarding unclear demographic data, design or outcomes of the included studies. Disagreements between the two authors were resolved by discussion, and two other senior investigators (Y.-S.P. and K.-L.C.) were consulted to attain a consensus.
Outcomes
In comparison of lower phosphate diets with higher phosphate diets, our outcome of interest was the difference in change-from-baseline FGF23 levels between dietary intervention groups in the included studies.
Data synthesis and analysis
Categorical variables are presented as frequencies or percentages, and continuous variables are presented as the mean values, unless stated otherwise. We calculated the mean change of FGF23 levels from baseline to the end of the trial for each intervention group and obtained the differences in the mean change of FGF23 levels between intervention groups. Considering the difference in measurement units between intact FGF23 (iFGF23) and C-terminal FGF23 (cFGF23) assays, the treatment effect was analysed as the standardized mean difference (SMD) with the 95% confidence interval (CI) and pooled by the meta-analysis [29] . The SMDs of 0.2, 0.5 and 0.8 are suggested corresponding to small, medium and large effects, respectively [31] . To facilitate pooling of the treatment effects from parallel and cross-over trials, we followed methods suggested by Elbourne et al. [32] , the Cochrane Handbook for Systematic Reviews of Interventions [29] and the statement from the Agency for Healthcare Research and Quality of the United States [31] (Supplementary data, Appendix 2). In particular, we manually computed SMD and standard error for each included study. Due to the small number of included studies, we used Hedges' g pool variances [29, 31, 32] . Because the included studies had different study periods, study designs and dietary phosphate amounts, we used the random-effects model as the primary method with which to calculate the pooled estimates for the effect measures of the included studies. The publication bias was examined using the funnel plot method and Egger's regression asymmetry test [33] . The heterogeneity of treatment effects across studies was assessed by I 2 and the Cochran's Q-test [29] .
We conducted subgroup analyses to explore the sources of heterogeneity across studies. Owing to the similar characteristics of included studies regarding age, sex, baseline kidney function and sample size, these variables were not assessed in the subgroup analyses. We assessed studies with different trial designs or those used different FGF23 assays in the subgroup analyses. To examine the robustness of our meta-analysis, we conducted sensitivity analyses by using imputed correlation values (r) obtained from the individual patient data provided by Di Iorio et al. [34] . For calculating pre-post correlation, we used r ¼ 0.6 for the lower phosphate diet group, r ¼ 0.9 for the higher phosphate diet group and r ¼ 0.9 or 0.6 for the standard error of SMD. Because the conversion between values from different assays has not yet been standardized, we converted the values from the cFGF23 assay (RU/mL) to those from the iFGF23 assay (pg/mL) by different conversion factors (equal, divided by 1.5 or divided by 2.08) [35] [36] [37] and expressed the effect size as mean difference (MD) with 95% CI. A two-sided test in which P 0.05, was considered statistically significant. Statistical analyses were performed with R software (version 3.2.4, R Foundation for Statistical Computing, Vienna, Austria).
R E S U L T S
Search results
The flow chart in Figure 1 shows the literature search process. By screening 110 articles, including 64 articles from Medline, 31 from PubMed, 8 from Embase and 7 from the Cochrane Library, 40 duplicates were removed. Of the remaining 70 articles, 64 were excluded based on their titles and abstracts. Of the six articles that underwent full-text evaluation, five met the inclusion criteria.
Study characteristics and quality assessments of the included studies
We enrolled five eligible RCTs with a total of 94 participants. The clinical characteristics of each study are summarized in Table 1 . Three cross-over trials had the same duration of dietary intervention for 1 week, and the remaining two parallel group trials had durations of 12 and 2 weeks, respectively. The participants had a median age of 62 years. All included studies consisted of non-dialysis CKD patients with a median estimated glomerular filtration rate (GFR) of 39 mL/min, classified as Stage 3B of CKD. At the time of recruitment, all study participants had normal serum phosphate levels (median value, 3.4 mg/dL). The assays used to measure FGF23 differed between the included studies; specifically, two studies [25, 27] used the cFGF23 assay from Immutopics International, San Clemente, CA, and the others [26, 34, 38] used the iFGF23 assay from Kainos Laboratories, Tokyo, Japan. The amount of phosphate in the diet varied between the studies, ranging from 350 mg/day to 900 mg/day for the lower phosphate diet group and from 600 mg to >2500 mg for the higher phosphate diet group. The 24-h urinary phosphate excretion decreased in the lower phosphate diet group of each study, and the percentage of change-from-baseline FGF23 levels varied across studies. The risk of bias for the included studies is summarized in Table S1 of the Supplementary data. Owing to the open-label design of the included studies, the lack of blinding of participants and personnel was the main cause of potential bias.
Effects of lower versus higher phosphate diet on FGF23 levels Figure 2 shows the pooled estimates for the study outcome. Compared with the higher phosphate diet, the lower phosphate diet tended to reduce FGF23 levels (SMD À0.74, 95% CI À1.54 to 0.07, P ¼ 0.07). The between-study heterogeneity was substantial for the study outcome (I 2 ¼ 85.3%, P < 0.01). The funnel plot showed more studies at an area with smaller effect size and Egger's regression asymmetry test was not significant (P ¼ 0.84), indicating that publication bias was less likely (Supplementary data, Figure S1 ).
Subgroup analyses and sensitivity analyses
Because the included studies used different FGF23 assays, we assessed whether the FGF23-lowering effect differed between the iFGF23 and the cFGF23 assays in the subgroup analysis. As shown in Figure 3 , there was a trend (P for interaction ¼ 0.09) towards a better FGF23-lowering effect by lower phosphate diets in studies using the iFGF23 assay (SMD À1.14, 95% CI À2.24 to À0.04, I
2 ¼ 90%) than those using the cFGF23 assay (SMD À0.05, 95% CI À0.67 to 0.57, I
2 ¼ 0%). Notably, studies using the iFGF23 assay were cross-over trials with a shorter study duration, and those using the cFGF23 assay were parallel trials with a longer study duration.
Sensitivity analyses by using imputed correlation values (r ¼ 0.6 for the lower phosphate diet group, r ¼ 0.9 for the higher phosphate diet group) are shown in Figure S2A (r ¼ 0.9 for the standard error of SMD) and Figure S2B (r ¼ 0.6 for the standard error of SMD) of the Supplementary data. Both Figure  S2A (SMD À0.80, 95% CI À1.65 to 0.06, P ¼ 0.07) and Figure  S2B (SMD À0.78, 95% CI À1.59 to 0.03, P ¼ 0.06) show that lower phosphate diets tended to reduce FGF23 levels and the effect sizes were similar to the main analysis. Sensitivity analyses that assessed different conversion factors between cFGF23 and iFGF23 are shown in Figure S3 of the Supplementary data. If we assumed that the values from the cFGF23 assay were equal to those from the iFGF23 assay, lower phosphate diets would show a significantly better FGF23-lowering effect (MD À30.17, 95% CI À59.68 to À0.66 pg/mL, P ¼ 0.045; Figure S3A , Supplementary data). If we converted the values from the cFGF23 assay to those from the iFGF23 assay by the conversion factors of 1.5 or 2.08, lower phosphate diets would show a trend towards a better FGF23-lowering effect, which is similar to the main analysis (Supplementary data, Figures S3B and S3C ).
Possible adverse effects of a lower phosphate diet
Three studies [26, 34, 38] assessed the effect of dietary intervention for a 1-week intervention period. Among them, one study [34] reported information on serum albumin levels and normalized protein catabolic rates and showed no betweengroup differences at the end of the trial. In the study reported by Moe et al. [26] , one of nine participants complained of hunger and dropped out of the study. In the study with the longest duration [27] , dietary intervention was provided for 12 weeks and there were no between-group differences in serum albumin levels or caloric intake.
D I S C U S S I O N
In this systematic review and meta-analysis of normophosphataemic patients with Stage 3B CKD, lower phosphate diets tended to show a better FGF23-lowering effect compared with higher phosphate diets. In addition, the FGF23-lowering effects of lower phosphate diets tended to be better in studies measuring with the iFGF23 assay. These estimates were fairly robust and showed few alterations in the sensitivity analyses.
Following a standard protocol, we used a comprehensive search strategy and applied rigorous methods to assess the robustness of the study results, including subgroup and sensitivity analyses. The identified studies enrolled participants with similar characteristics with respect to age, kidney function, serum phosphate level and study size. All included studies measured 24-h urinary phosphate excretion to confirm the compliance of dietary intervention, which further strengthened our findings. Our results provide valuable information for future clinical studies assessing FGF23 and dietary intervention in patients with CKD.
In a systematic review assessing effects of dietary intervention on mineral and bone disorder in patients with CKD, Liu et al. [28] reported no significant difference in FGF23 levels with lower phosphate diets compared with higher phosphate diets. However, this systematic review addressed the effect of a variety of dietary interventions on mineral and bone disorders, and only one study assessing FGF23 was included [27] . In contrast, our systematic review was designed to focus on the effects of dietary intervention on FGF23 levels in patients with CKD, and utilized meta-analyses to pool the results from available literatures. Our study not only showed the potential FGF23-lowering effect by phosphate restriction, but also found that dietary phosphate intervention might have different effects among FGF23 levels measured with different assays.
In a dietary phosphate intervention study on adults with normal kidney function, Burnett et al. demonstrated that changes in FGF23 were more prominent when measured with the iFGF23 assay [39] . They also reported that FGF23 levels measured with the iFGF23 assay was significantly associated with serum phosphate and 24-h urinary phosphate excretion, but the association was not significant when using the cFGF23 assay [39] . In studies evaluating phosphate binders in patients with CKD, the changes in levels of cFGF23 showed neutral results, which implied that measurement with the cFGF23 assay might not be sensitive enough to detect the changes in biologically active FGF23 levels [40, 41] . The reason why changes in levels of FGF23 were detected with the iFGF23 assay but not with the cFGF23 assay might be due to increased proteolytic cleavage of iFGF23 protein by dietary phosphate restriction, leading to lower levels of iFGF23 but no change for cFGF23, which also acted as an antagonist in the regulation of FGF23 bioactivity [42, 43] . Our finding that dietary phosphate restriction influenced iFGF23 but not cFGF23 implies a novel regulatory pathway in phosphate control among CKD patients, and Included four subjects using lanthanum carbonate in each intervention group.
Ad libitum, as desired; cFGF23, C-terminal fibroblast growth factor-23; eGFR, estimated glomerular filtration rate; iFGF23, intact fibroblast growth factor-23; NA, not available; P, phosphate.
future studies should measure FGF23 with both iFGF23 and cFGF23 assays to assess the discordant effects. Included studies with the iFGF23 assay were cross-over trials with a shorter study duration of 1 week, while those with the cFGF23 assay were parallel trials with a longer study duration of up to 12 weeks. Because iFGF23 and cFGF23 had a similarly short half-life of <1 h and the half-life was only mildly prolonged in patients with decreased GFR [44, 45] , the differences in study durations between parallel and cross-over trials were less likely to explain the more prominent changes in FGF23 when measured with the iFGF23 assay. However, whether the trial designs influence the changes in FGF23 between different dietary interventions requires further studies to investigate.
Our study has several limitations. First, all the included studies assessed the efficacy of lower phosphate diets in patients with CKD Stage 3B, and no study has evaluated dialysis patients even though this population has a higher prevalence of hyperphosphataemia and more prominently elevated levels of FGF23. Future RCTs should enroll patients undergoing dialysis to investigate the effect of a dietary intervention on FGF23 levels. Secondly, the participant numbers of included studies were small and most of the studies had a short duration, which limited the power of the analyses. Thus, the finding of our systematic review can only be interpreted as short-term effects of dietary intervention on the changes of FGF23, and studies with a larger population and longer duration are warranted. Thirdly, Pooled estimates comparing effects of lower phosphate diets with higher phosphate diets on changes in FGF23 levels. The treatment effects are expressed as the SMD with the 95% CI. Lower phosphate diets provide a better lowering effect on the FGF23, if the pooled estimate is significantly less than zero. lower P, lower phosphate; higher P, higher phosphate; W, weight. Subgroup analysis comparing effects of lower phosphate diets with higher phosphate diets on changes in FGF23 levels, by different measurement assays. The treatment effects are expressed as the SMD with the 95% CI. Lower phosphate diets provide a better lowering effect on the FGF23, if the pooled estimate is significantly less than zero. P for interaction between subgroups ¼ 0.09. Studies using the iFGF23 assay had a cross-over design, and those using the cFGF23 assay had a parallel design. cFGF23, C-terminal fibroblast growth factor-23; iFGF23, intact fibroblast growth factor-23; lower P, lower phosphate; higher P, higher phosphate; W, weight.
Lower phosphate diet and FGF23 the characteristics of the included studies are diverse in terms of the study design, FGF23 assay, intervention period and definition of a lower or higher phosphate diet. Therefore, we used random-effects meta-analyses to minimize the potential bias. Despite our efforts in the subgroup analyses to explore sources of heterogeneity, we could only partially explain the heterogeneity from the types of FGF23 assays. Further exploration with multivariable meta-regression or multilevel subgroup analyses was not feasible due to the relatively small number of included studies. Finally, this systematic review included information from published studies only. Although tests for publication bias did not show significance, such bias could still exist because of the relatively low power of the tests.
In conclusion, our systematic review indicates that shortterm dietary phosphate restriction tends to reduce FGF23 levels in adult patients with moderately decreased kidney function. In addition, the FGF23-lowering effects of lower phosphate diets tend to be more prominent when measured with the iFGF23 assay.
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